A Study of Glycemic Control in Left Ventricular Assist
About this study
The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.
- Condition
- Type 2 Diabetes Mellitus, Hyperglycemia, Hypoglycemia
- Tested
- Freestyle Libre 3 Continuous Glucose Monitor (CGM)
- Sponsor
- Mayo Clinic
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 8
- Minimum age: 18 years
- Study condition: Type 2 Diabetes Mellitus, Hyperglycemia, Hypoglycemia
- Prior implantation of contemporary, centrifugal flow LVAD (HeartWare or HeartMate 3) at any time after 2010
- Diagnosis of type II diabetes mellitus
- Any antihyperglycemic regimen
- Greater than 3 months out from LVAD implantation
- Capable of utilizing smartphone device for LibreLink app for uploading glycemic data
- Patients may be enrolled who have preexisting CGM in place.
Exclusion 3
- Type I diabetics
- Unable to return at 3 month evaluation
- Unwillingness to participate
Where
1 site, 1 recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Contact
-
Sarah Schettle, PA-C
(507) 293-1375 Schettle.Sarah@mayo.edu
-
Andrew Rosenbaum, MD
(507) 284-0783 Rosenbaum.Andrew@mayo.edu
Potential match only. Final eligibility is determined by the study team.